Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.

Abstract

BACKGROUND:

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions show dramatic responses to specific tyrosine kinase inhibitors (TKIs); however, after 10-12 months, secondary mutations arise that confer resistance. We generated a murine xenograft model using patient-derived NSCLC cells isolated from the pleural fluid of two patients with NSCLC to investigate the mechanisms of resistance against the ALK- and EGFR-targeted TKIs crizotinib and osimertinib, respectively.

METHODS:

Genotypes of patient biopsies and xenograft tumors were determined by whole exome sequencing (WES), and patients and xenograft-bearing mice received targeted treatment (crizotinib or osimertinib) accordingly. Xenograft mice were also treated for prolonged periods to identify whether the development of drug resistance and/or treatment responses were associated with tumor size. Finally, the pathology of patients biopsies and xenograft tumors were compared histologically.

RESULTS:

The histological characteristics and chemotherapy responses of xenograft tumors were similar to the actual patients. WES showed that the genotypes of the xenograft and patient tumors were similar (an echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) gene fusion (patient/xenograft: CTC15035EML4-ALK) and EGFR L858R and T790M mutations (patient/xenograft: CTC15063EGFR L858R, T790M)). After continuous crizotinib or osimertinib treatment, WES data suggested that acquired ALK E1210K mutation conferred crizotinib resistance in the CTC15035EML4-ALK xenograft, while decreased frequencies of EGFR L858R and T790M mutations plus the appearance of v-RAF murine sarcoma viral oncogene homolog B (BRAF) G7V mutations and phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha (PIK3C2A) A86fs frame shift mutations led to osimertinib resistance in the CTC15063EGFR L858R, T790M xenografts.

CONCLUSIONS:

We successfully developed a new method of generating drug resistance xenograft models from liquid biopsies using microfluidic technology, which might be a useful tool to investigate the mechanisms of drug resistance in NSCLC.

• Authors: Yunhua Xu, Feifei Zhang, Xiaoqing Pan, Guan Wang, Lei Zhu, Jie Zhang, Danyi Wen, Shun Lu
• Journal: Cancer communications (London, England) (Cancer Commun (Lond)) Vol. 38 Issue 1 Pg. 19 (05 09 2018) ISSN: 2523-3548 [Electronic] United States
• PMID: 29764505 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Acrylamides
• Aniline Compounds
• Piperazines
• Protein Kinase Inhibitors
• osimertinib
• Crizotinib
• PIK3C2A protein, human
• Anaplastic Lymphoma Kinase
• ErbB Receptors
• BRAF protein, human
• Proto-Oncogene Proteins B-raf

Topics

• Acrylamides
• Anaplastic Lymphoma Kinase (genetics)
• Aniline Compounds
• Animals
• Carcinoma, Non-Small-Cell Lung (complications, drug therapy, genetics)
• Crizotinib (pharmacology)
• Drug Resistance, Neoplasm (drug effects, genetics)
• ErbB Receptors (genetics)
• Female
• Humans
• Lung Neoplasms (complications, drug therapy, genetics)
• Mice, SCID
• Mutation
• Phosphatidylinositol 3-Kinases (genetics)
• Piperazines (pharmacology)
• Pleural Effusion, Malignant (complications)
• Protein Kinase Inhibitors (pharmacology)
• Proto-Oncogene Proteins B-raf (genetics)
• Xenograft Model Antitumor Assays (methods)